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Recombinant alpha-interferon as salvage
therapy in multiple myeloma
A pilot study
P. JACOBS, INGRID M. LE ROUX, LUCILLE WOOD, HELEN S. KING
Summary
Ten patients with end-stage multiple myeloma refractory to
conventional chemotherapy and hemibody irradiation received
recombinant a-interferon as salvage therapy. The median
duration of treatment was 8 weeks. One patient had an
objective response and survived 8 months, whereas in the
remaining 9 patients the disease progressed and median
survival was 11,5 weeks. Side-effects were substantial and
included confusion with extreme weakness, resulting in 5
patients refusing further therapy. The low response rate and
the morbidity in this pilot study resulted in its discontinuation
and the conclusion that recombinant a-interferon as single-
agent therapy used for salvage in patients with refractory
myeloma is of no value.
S AIr Med J 1989; 76: 100-102.
Myeloma is at present considered incurable, although objective
response can be achieved with single agents l or multiple drug
combinations2-4 leading to modest prolongation in survival.
The quality of life is generally improved during this period by
optimal supportive care aimed at reversal of metabolic abnor-
malities and relief of pain using local radiotherapy. However,
loss of disease control usually occurs within 2 - 3 years and
salvage therapy is then of limited benefit, although a number
of alternative options exist. The latter include newer drug
programmeSS and high-dose chemotherapy followed by auto-
logous bone marrow transplantation in which ex vivo purging
may be used to remove contaminating malignant cells.6 In
view of the activity of recombinant a-interferon in hairy-eell
leukaemia7 and the use of this product in myeloma,8,9 a pilot
study was undertaken to define patient acceptability, docu-
ment side-effects and explore response rates in patients who
had relapsed and become refractory to conventional therapy.
Patients and methods
Ten patiepts between the ages of 47 years and 68 years with a
confirmef diagnosis of myeloma lO were entered into a pilot
study th~t had received approval from the Ethics Committee
of the niversity of Cape Town Medical School and where
participation required informed consent.
All 10 patients were heavily pretreated for a median of 28
months (range 9 - 47 months); 1 received melphalan and
prednisone only, 1 received melphalan, prednisone and cyclo-
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phosphamide, and the other 8, combinations of chemotherapy
and sequential half-body radiotherapy. All had a response to
initial treatment, but had relapsed (Table I). Recombinant a-
interferon was given on two schedules, both recommended by
the supplier. Three patients received 150 x 106 units intra-
venously once a month, and 18 x 106 units subcutaneously 3
times a week (schedule A), 5 patients received daily sub-
cutaneous a-interferon at a dose of 3 - 9 X 106 units from
commencement of treatment (schedule B), and the remaining
2 patients started off on schedule A and were switched to
schedule B within 3 months. Median duration of treatment
was 8 weeks (range I - 28 weeks). Response was def"med as a
50% reduction in paraprotein and improved Karnofsky per-
formance status. I I
Results
One patient met the criteria for response. However, this
patient had an intracerebral myelomatous deposit that in-
creased in size during therapy and he was withdrawn from the
trial after 7 months, when all disease control was lost. In the
remaining 9 patients there was rapid progression of their
myeloma and 3 died at 1, 2, and 3 weeks respectively after
starting treatment; these patients are unsuitable for further
comment. The a-interferon was not considered to have con-
tributed to the death of any of these individuals.
SignIficant side-effects were encountered during the course
of a-interferon adIninistration on· both schedules. However,
the 5 patients who received higher initial doses had more
prominent chills and fever spikes, but in all individuals these
could be controlled with antipyretics.
Four patients complained of extreme tiredness and weakness,
4 lost their appetites and 3 experienced nausea. Two patients
developed raised liver enzymes and in 1 there was persistent
tachycardia on treatment. Mental confusion occurred in 4
patients. In 5 patients a-interferon had to be discontinued at
4, 7, 8, 8 and 14 weeks respectively because of these side-
effects: dose reduction was offered to these. individuals, but
none was willing to accept further treatment. Haematological
toxicity in all these patients was insignificant.
Discussion
Of the 10 patients treated with recombinant a-interferon in
this pilot study there was 1 responder (10%). This low figure
compares with previous reports8,9 of response rates respectively
of 8% in a group of 12 treated and untreated patients and 14%
in previously untreated patients with myeloma. Similarly, in
21 patients with all stages of multiple myeloma treated with
a-interferon between 1978 and 198012 only 3 of the 12 pre-
viously untreated individuals (25%) had a reduction in tumour
mass greater than 50%, with 1 patient relapsing and 1 patient
previously unresponsive to chemotherapy also having the
immunoglobulin level reduced by > 50%. However, in a
further report from the same institution13 6 of 10 patients with
multiple myeloma responded to a-interferon therapy.
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TABLE I. SUMMARY OF PREVIOUS THERAPY, a-INTERFERON SCHEDULE AND SIDE-EFFECTS
Previous Interferon Response
treatment schedule and
























M = melphalan;·P = prednisone; C'= cyclophosphamide; V =vincristine; DXR = half-body radiotherapy.
Results of our study were inferior to alternative salvage
programmes, such as the vincristine-adriamycin-dexamethasone
combination,5 although 7 of the 10 patients had IgG myeloma,
which is a subgroup believed to have the lowest response rate
to a-interferon.8 Side-effects were also more severe in this
series than previously reported, with extreme tiredness and
mental confusion requiring interruption and eventual discon-
tinuation of therapy in 50% of the individuals. All our patients
had received previous treatment over long periods of time and
their disease was rapidly progressing when a-interferon was
commenced as salvage therapy.
It is concluded from this pilot study and similar published
results14 that recombinant a-interferon is without benefit when
used as a single agent in patients with myeloma who have
relapsed or are resistant to conventional cytotoxic and radio-
therapy programmes. However, the role of this agent remains
to be clarified, since a therapeutic effect has been reported in
previously untreated patients t5 and those in first relapse fol-
lowing previous response to chemotherapy regimens. 16
Furthermore, there may be a place for alternative programmes
in which interferon is combined with conventional cytotoxic
chemotherapeutic agentsY
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non-chronic users of cannabis is more probably mediated by
the microsomal oxidase enzyme system in the liver.
The range of clinical, intOXicating, psychological and psychia-
tric effects of cannabis ('dagga') are reviewed. Controversial
subjects, such as the entities of toxic cannabis psychosis and
the cannabis amotivational syndrome, are discussed.
S Air Med J 1989; 76: 102-104.
Cannabis saliva ('dagga') affects the central nervous system
(CNS) in a variety of ways although its biochemical modes of
action are unknown. There is some evidence to suggest that
o.-9-tetra-hydrocannabinol (0.-9-THC), the most psychically
active constituent, effects serotonin metabolism in the brain by
increasing serotonin release from reserpine-sensitised sites by
causing a shift from the bound to the free intraneuronal pool
of serotonin and by causing an increased rate of serotonin
synthesis from serotonin precursors. I-3
There is also evidence to suggest that cannabinoids interact
with other psycho-active drugs and can potentiate the effects
of alcohol, caffeine, emphetamines and barbiturates in man.4.~
This phenomenon could be a potentiation in the CNS but in
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Clinical effects
The typical immediate physical effects of cannabis use include
dry mouth and throat, tachycardia, postural hypotension, con-
junctival vessel injection that causes red eyes and leaves the
pupils unaffected, and mild initial bronchoconstriction followed
by bronchodilation. Tachycardia is probab?-: the most reliable
index of physiological response to cannabis. -8
The major intoxication effects of cannabis include mood
elevation and a feeling of well-being and perceptual and
sensory distortions. Both external senses and internal stimuli
are enhanced and experienced as more intense and meaningful.
Time and distance perception are distorted. Libido and appetite
may be enhanced and short-term memory and judgement may
be impaired. These effects usually last for up to 8 hours.9-l2
These central changes may be reflected in alterations in
electrical activity.13,14 The electro-encephalographic signs of
cannabis use in man are not clear cut. Early reports described
a reduction in a-wave activity with an increase ,B-activity for
up to 6 days after cannabis use,15,16 while others have demon-
strated an increase in a-wave and a reduction in ,B-wave
activity.17.18 Some studies demonstrated a dose-response re-
lationship with altered electro-encephalographic patterns and
suggested that a tissue tolerance to cannabis develops, since
chronic users demonstrated these changes only with increasing
doses of cannabis. 17,19.20 Hollister el al. 17 have suggested that
these changes are nonspecific effects caused by relaxation and
setting.
To date there is no convincing evidence that cannabis use
causes brain dama~e, despite earlier reports of cerebral atrophy
in cannabis users. 1 .21
